Effects of exercise during active surveillance for prostate cancer: A systematic review and meta-analysis
- PMID: 38833183
- DOI: 10.1007/s00520-024-08606-z
Effects of exercise during active surveillance for prostate cancer: A systematic review and meta-analysis
Abstract
Purpose: The efficacy of exercise in men with prostate cancer (PCa) on active surveillance (AS) remains unclear. In this meta-analysis, we aimed to examine the effects of exercise in PCa patients on AS.
Methods: A literature search was conducted in PubMed, EMBASE, and the Cochrane Library using search terms, including exercise, PCa, AS, and randomized controlled trials (RCTs). The means and standard deviations for peak oxygen consumption (VO2peak), prostate-specific antigen (PSA) levels, and quality of life (QoL) were extracted for the intervention and control groups. A random-effects model was used to summarize the effects of exercise.
Results: Of the 158 identified studies, six RCTs with 332 patients were included. The interventions included lifestyle modifications (aerobic exercise + diet) in three studies and different exercise modalities in three studies. The intervention duration was 2-12 months; three interventions were supervised and three were self-directed. The pooled weighted mean difference between exercise and usual care for VO2peak was 1.42 mL/kg/min (95% confidence interval [CI]: 0.30 to 2.54, P ≤ 0.001). A non-significant effect was observed for QoL (pooled standardized mean difference [SMD]: 0.24, 95% CI: - 0.03 to 0.51, P = 0.08) which became statistically significant and stronger after excluding one outlier study (P < 0.001). Exercise also had a positive effect on PSA levels (pooled SMD: - 0.43, 95% CI: - 0.87 to 0.01, P = 0.05).
Conclusion: Exercise improves cardiorespiratory fitness and may improve QoL and PSA levels in men with PCa on AS. Further studies with larger sample sizes are warranted to obtain more reliable results.
Keywords: Active surveillance; Cardiorespiratory fitness; Exercise; Meta-analysis; Prognosis; Prostate cancer.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63:597–603. https://doi.org/10.1016/j.eururo.2012.11.005 - DOI - PubMed
-
- Parker C (2004) Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5:101–106. https://doi.org/10.1016/S1470-2045(04)01384-1 - DOI - PubMed
-
- Sanghera S, Mohiuddin S, Coast J, Garfield K, Noble S, Metcalfe C, Lane JA, Turner EL, Neal D, Hamdy FC, Martin RM, Donovan JL, Bollina P, Doble A, Doherty A, Gillatt D, Gnanapragasam V, Hughes O, Kockelbergh R, Kynaston H, Paul A, Paez E, Rowe E (2020) Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial. BMC Cancer 20:971. https://doi.org/10.1186/s12885-020-07276-4 - DOI - PubMed - PMC
-
- Kronenwetter C, Weidner G, Pettengill E, Marlin R, Crutchfield L, McCormac P, Raisin CJ, Ornish D (2005) A qualitative analysis of interviews of men with early stage prostate cancer: the Prostate Cancer Lifestyle Trial. Cancer Nurs 28:99–107. https://doi.org/10.1097/00002820-200503000-00003 - DOI - PubMed
-
- Ornish DM, Lee KL, Fair WR, Pettengill EB, Carroll PR (2001) Dietary trial in prostate cancer: early experience and implications for clinical trial design. Urology 57:200–201. https://doi.org/10.1016/s0090-4295(00)00974-2 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
